Introduction: Implantation of a ventricular assist device (VAD) is a seminal therapeutic option for patients with terminal cardiac failure. However, haemolysis remains a clinically relevant adverse effect of several VAD types. Lysed erythrocytes release lactate dehydrogenase (LDH) and haemoglobin. Free haemoglobin in plasma is bound by haptoglobin with high affinity. The complex is internalised by monocytes/macrophages and degraded. Any more released free haemoglobin is captured by haemopexin. This complex also undergoes lysosomal degradation in various cells. Only now, the excessive free haemoglobin can be measured in plasma. Here, we investigated haemolysis in patients supported by different VAD types. Methods: Five patients with an intracorporeal centrifugal left ventricular VAD (LVAD), 10 patients with an axial LVAD and seven patients with a paracorporeal biventricular assist device (BVAD) were analysed preoperatively and 3 days (3.0 AE 0.4 days, early), 2 weeks (14 AE 1 days, intermediate) and 2 months (62 AE 5 days, later) after VAD implantation for haptoglobin, haemopexin, free haemoglobin in plasma, LDH, total haemoglobin, haematocrit and transfusion requirements. Results: Patients with a centrifugal LVAD displayed normal haptoglobin and haemopexin, low free haemoglobin and moderately increased LDH. In comparison, axial LVADs were accompanied by lower haptoglobin and haemopexin and higher free haemoglobin and LDH values. In contrast, BVADs led to an almost complete loss of haptoglobin and haemopexin and to high levels of free haemoglobin and LDH at each analysed time point. Conclusions: While severe haemolysis accompanies BVAD support, erythrocyte damage is less pronounced in the axial LVAD examined and only slight in the intracorporeal centrifugal LVAD. Haemopexin, a scavenger of free haemoglobin, can be used, in combination with haptoglobin and free haemoglobin, to assess erythrocyte damage. #
Introduction
Implantation of a ventricular assist device (VAD) is a seminal therapeutic option for patients with terminal cardiac failure. A growing number of VAD patients are successfully bridged to transplantation, can be weaned or can even live permanently with the device. However, the success is restricted by frequent severe complications. Haemolysis is a relevant adverse effect of several VAD types. Destruction of red blood cells (RBCs) is the result of wall shear stress, flow acceleration and interaction with artificial surfaces [1] . It contributes, together with the specific bleeding problems, [2, 3] to debilitating anaemia in VAD patients.
Lysed erythrocytes release lactate dehydrogenase (LDH) and haemoglobin. Free haemoglobin in plasma is often used to characterise the extent of haemolysis and can be analysed photometrically in most clinical laboratories. However, measurement of free haemoglobin in plasma is prone to pre-analytical disturbances such as faulty blood sampling and interference from high bilirubin levels, turbidity, methemalbuminaemia or lipaemic plasma. Therefore, judgement of haemolysis should not rely only on free haemoglobin.
Free haemoglobin in plasma (the so-called stroma-free haemoglobin) is bound by haptoglobin with high affinity. The complex binds to the transmembrane receptor CD163 on monocytes and macrophages. Subsequently, the complex is internalised and degraded [4] . In consequence, the haptoglobin serum level decreases down to entire depletion. Any more released free haemoglobin is captured by haemopexin. This complex attaches to the CD91 receptor, which is expressed by several cell types including hepatic parenchymal cells. The haemoglobin-haemopexin complex is taken up by the cell and undergoes lysosomal degradation [5] . Thus, haemopexin also vanishes from the serum. Only now, the excessive free haemoglobin can be measured in plasma [6] ( Fig. 1) .
In this study, we conduct an analysis of haemolysis in patients with different VAD types by assessment of haptoglobin, haemopexin and free haemoglobin. We compare three different VADs: two left ventricular systems, that is, a implantable centrifugal pump [7] and an implantable axial pump [8] and a paracorporeal pneumatic system with two chambers which supports both ventricles [9] .
Methods

Patients
Five patients with an intracorporeal centrifugal LVAD (centrLVAD; VentrAssist W , Ventracor Limited, Chatswood, Australia), 10 patients with an axial left ventricular assist device (axLVAD; HeartMate II W ; Thoratec Corporation, Pleasanton, CA, USA) and seven patients who received biventricular VAD (BVAD) support were included in this study. The BVAD consisted of two Thoratec PVAD W devices (Paracorporeal Ventricular Assist Device). All patients underwent VAD implantation between August 2006 and June 2008 at our centre. Postoperatively, six of the overall 22 patients needed dialysis and two of the 15 LVAD patients had temporary mechanical right-ventricular support.
Data were analysed preoperatively and 3 days (3 AE 0.4 days), 2 weeks (14 AE 1 days) and 2 months (62 AE 5 days) after VAD implantation. These dates typically reflect an early postoperative, an intermediate and a later state in the course after VAD implantation.
No pre-existing haemolytic or bleeding disorder was known in any of the patients. Data were obtained from routinely taken blood samples. The study was approved by the institutional ethics committee.
Surgical procedures
VentrAssist and HeartMate II are left ventricular intracorporeal devices. Implantation was performed through routine median sternotomy. The inflow graft was inserted into the left ventricular apex and the outflow graft was anastomosed to the ascending aorta.
The VentrAssist is a centrifugal pump. The moving part is a hydrodynamically suspended impeller. A basal speed of about 1200 rpm is necessary to keep the rotor flowing on the blood. Typical operating speed is 1900-2200 rpm. The axial pump HeartMate II is operated by a spinning rotor, which is mounted on a bearing. Typical operating speed is 9000 rpm.
The Thoratec BVAD contains two paracorporeal pump chambers. The inflow cannula of the right VAD was implanted in the right atrium in two of the five cases. Currently, we use the right ventricular apex as the preferred cannulation site (three of five patients). The right ventricular outflow graft was anastomosed to the main pulmonary artery. The two pump chambers are connected to the inflow and outflow cannulae and driven by pneumatic power. Alternating positive and negative air pressure actuates a flexible blood sac within the rigid outer casing of the pump. Mechanical tilting-disc valves in the inflow and outflow ports ensure unidirectional blood flow through the device. Pumping frequency and stroke volume are adjusted to the physiological requirement of the patients.
Anticoagulation for all three systems was started with heparin with a target partial thromboplastin time (PTT) of 60-80 s. It was changed to phenprocoumon after removal of the chest drains and sufficient oral ingestion. Target INR was 2.8-3.2 for the VentrAssist, 2.0-3.0 for the HeartMateII and 3.0-3.5 for the Thoratec BVAD according to the devicedependent risk for thrombosis. Platelet aggregation was inhibited by acetylsalicylic acid (ASA) 100 mg day À1 and adjusted according to the results of aggregometry with stimulation by collagen, arachidonic acid, adenosine 5 0 -diphosphate (ADP) and ristocetin.
Laboratory analysis
Haptoglobin and haemopexin were measured using antibody-based turbidimetric tests (antibodies: Roche, Mannheim, Germany Dade Behring, Marburg, Germany, reader: Modular).
Free haemoglobin in plasma was calculated after direct photometry at 380, 415 and 450 nm (Harboe method) on a spectral photometer (LS 500, Lange, Berlin, Germany). Total haemoglobin was assessed photometrically (SE-9000, Sysmex, Norderstedt, Germany) and haematocrit by measuring impedance (XE-2100, Sysmex). LDH activity was measured enzymatically according to the IFCC method (Roche).
Statistics
Data were analysed using the SPSS 15.0 software. All values are expressed as mean AE standard deviation. One-way analysis of variance (ANOVA) with post hoc Bonferroni correction was employed to assess differences between the three groups (centrLVAD, axLVAD and BVAD). A p < 0.05 was considered significant.
Results
Twenty-two VAD patients (mean age 50 AE 17 years) were included in the analysis. Reasons for cardiac failure were dilatative cardiomyopathy in 10 patients, ischaemic cardiomyopathy and myocarditis in five patients, respectively, and amyloidosis and muscular dystrophy in one patient each.
We analysed the haemolysis-related parameters such as haptoglobin, haemopexin, free haemoglobin in plasma and LDH (Table 1 ) and the anaemia-related values such as total haemoglobin, haematocrit and number of required packed red blood cell (RBC) transfusions (Table 2) .
Preoperative values are given in Tables 1 and 2 . We refrained however from statistical analysis due to the small groups.
After implantation, patients with a centrLVAD displayed normal haptoglobin and haemopexin, low free haemoglobin and moderately increased LDH. In comparison, axLVADs were accompanied by lower haptoglobin and haemopexin values and higher free haemoglobin and LDH values. In contrast, BVADs led to an almost complete loss of haptoglobin and haemopexin and to high levels of free haemoglobin and LDH at each analysed time point. Fig. 2 displays the late data after 2 months.
Patients with a centrLVAD maintained higher haptoglobin at day 60 compared to axLVAD carriers. In comparison to the values of BVAD patients, haptoglobin and haemopexin were always better in centrLVAD patients. Haptoglobin in BVAD and axLVAD patients was comparable by statistical means. However, more haemopexin was lost in BVAD than in centrLVAD and axLVAD recipients at all times. Release of free haemoglobin was higher on day 3 and of LDH at each time point in BVAD compared to centrLVAD and axLVAD patients (Table 1) .
Mild anaemia was present in all patients. The number of required transfusions did not differ significantly due to high inter-individual variation (Table 2 ).
Discussion
Haemolysis is a typical adverse phenomenon following implantation of a cardiac assist device. It is a relevant problem especially in severely ill patients with an impaired cardiovascular system. Unbound haemoglobin effectively Table 1 Haemolysis-related parameters were examined preoperatively and 3 days, 2 weeks and 2 months after implantation of different types of assist-devices. HB, total haemoglobin; HKT, haematocrit; PRBC, packed red blood cells; n.a., not analysed. There are no differences between the devices.
scavenges nitric oxide and, in doing so, further hampers haemodynamic regulation [10] . We investigated patients with three different VAD types: two continuous-flow left ventricular systems driven by a centrifugal and an axial pump, respectively, and a pulsatileflow biventricular support actuated by two pneumatic pump chambers. Our data indicate almost no haemolysis with the centrifugal pump, moderate cellular destruction by the axial pump and severe haemolysis with the biventricular system. These differences are due to the different designs of the devices. The centrifugal VentrAssist contains no bearings. The rotor swims on blood and carries four impellers which expel the blood. The axial HeartMate II drives the blood by a screw. Due to the construction, the VentrAssists operates on a slower speed than the HeartMate II. The Thoratec PVAD is operated pneumatically and therefore creates a suction to fill the chambers which results in high shear stress. Moreover, it contains mechanical valves.
In clinical practice, haemolysis is also a valuable parameter to assess the proper function of the VAD. An unexpected increase of haemolysis can indicate, for example, a thrombus or a shift or malpositioning of the VAD inflow cannula.
Free haemoglobin is routinely used to analyse RBC destruction. However, there is no accurate method for reliable and cost-effective measurement [12] . The main reasons for false-positive values are haemolysis during blood sampling and a high bilirubin level, which is commonly observed in VAD patients. Hepatic dysfunction due to hepatic sinusoid endothelial dysfunction [13] and inflammatory responses [14] accompany right ventricular failure [15] and poor postoperative liver perfusion [16] . Free haemoglobin appears if 1% of erythrocytes are lysed per day. Actually, lab readings for free haemoglobin are a 1000-fold lower than those for total haemoglobin (mg dl À1 vs g dl À1 ). Depletion of haptoglobin accompanies already slight haemolysis. Low or completely depleted haptoglobin is often observed following blood transfusions or in patients with a left ventricular outflow stenosis or with heart valve prosthesis, since these conditions are accompanied by a certain degree of haemolysis [11, 17, 18] . Haptoglobin is an acute-phase protein, but inflammatory processes do not seem to influence the plasma level in haemolytic patients. However, reduced synthesis due to liver function impairment can result in abnormal low levels without haemolysis [19] .
Thus, neither free haemoglobin nor haptoglobin are entirely dependable data for quantification of haemolysis. The 'backup' haemoglobin scavenger haemopexin has been described in cardiovascular surgery several years ago [11] but it has not become a widely employed method in this field for unknown reasons. Measurement of haemopexin avoids the disadvantages of free haemoglobin and haptoglobin described above. Our results support its consideration as a reliable and cost-effective supplemental parameter for assessment of haemolysis in cardiovascular patients [20] .
There are several limitations of our study. We only analysed a small number of patients and only one VAD system per principle of function. In addition, four of the five VentrAssist patients were included in the BRACE clinical trial ('Better Results and Cost Effectiveness') sponsored by Ventracor Ltd. and met the narrow inclusion criteria. More severely ill patients received the HeartMate II LVAD or the BVAD.
The data obtained early after VAD implantation can be overlayed by haemolysis due to the surgical procedure and multiple transfusions. However, we assume that haemolysis due to shear stress, which is caused by VAD support, is already prevalent early after implantation.
No direct comparison of these three systems has been undertaken so far to our knowledge. However, our results are consistent with previous studies, which indicate low haemolysis in the axial HeartMate II system in patients [21] and negligible haemolysis by the centrifugal VentrAssist device in experimental studies [22, 23] . These observations Fig. 2 . Haemolysis-related parameters approximately 2 months after assist-device implantation. Significant differences between the VAD types are indicated. The boxes contain the middle 50% of the values (25th and 75th percentile), the median is marked. The whiskers indicate the upper and lower non-extreme values. Circles mark outliers (distance from the box between 1.5-to 3-fold length of the box), asterisks mark extreme values (distance from the box more than 3-fold length of the box).
correlate to a higher revolution speed of the axial pump. In comparison, the Thoratec BVAD consists of two pneumatic pump systems with mechanical valves. Analysis of blood flow and shear stress obtained by computer simulations [24] and magnetic resonance (MR) analysis [25] could contribute to design less aggressive biventricular support systems.
Conclusion
Our data indicate that severe haemolysis accompanies BVAD support, whereas erythrocyte damage is less pronounced in the examined axial LVAD and only slightly in the intracorporeal centrifugal LVAD. Haemopexin, a scavenger of free haemoglobin, can be used, in combination with haptoglobin and free haemoglobin, as a laboratory parameter to assess erythrocyte damage.
